Kristina Kriksciukaite

Author

Enveda Therapeutics (United States)

Also Known As

K. Kriksciukaite, Kristina Kriksciukaite

Publications

295

Citations

H-Index

Concepts

All Affiliations

Enveda Therapeutics (United States)Sarah Cannon London Cancer The University of Texas MD Anderson Cancer Center Massachusetts General Hospital

About

Kristina Kriksciukaite is an author at Enveda Therapeutics (United States) specializing in medicine, pharmacology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	124
2	Health Sciences	2	2	52
3	Natural Sciences	1	1	12
4	Social Sciences	1	1	19
5	Anesthesia	1	1	30

Kristina Kriksciukaite

Publications

269

Citations

H-Index

Page 1

	Year	Citations
Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer Kerry A. Whalen, Brian H. White, James M. Quinn, Molecular Cancer Therapeutics	2019	66
Discovery of an SSTR2-Targeting Maytansinoid Conjugate (PEN-221) with Potent Activity in Vitro and in Vivo Brian H. White, Kerry A. Whalen, Kristina Kriksciukaite, Journal of Medicinal Chemistry	2019	50
Overriding the blockade of antinociceptive actions of opioids in rats treated with extended-release naltrexone Reginald L. Dean, Mark S. Todtenkopf, Daniel R. Deaver, Pharmacology Biochemistry and Behavior Extended-release NaltrexoneHealth SciencesPain MedicineAddictionMedicine	2008	30
Pen-866, a miniature drug conjugate of a heat shock protein 90 (HSP90) ligand linked to SN38 for patients with advanced solid malignancies: Phase I and expansion cohort results. Gerald S. Falchook, Johanna C. Bendell, Susanna V. Ulahannan, Journal of Clinical Oncology PathologyPharmacotherapyExpansion Cohort ResultsTumor BiologyPre-clinical Pharmacology	2020	26
First in human phase 1/2a study of PEN-221 somatostatin analog (SSA)-DM1 conjugate for patients (PTS) with advanced neuroendocrine tumor (NET) or small cell lung cancer (SCLC): Phase 1 results. Melissa L. Johnson, Tim Meyer, Daniel M. Halperin, Journal of Clinical Oncology Cancer ManagementImmunologyPathologyPharmacotherapyPreliminary Efficacy	2018	22
PRECLINICAL STUDY: Route of administration affects the ability of naltrexone to reduce amphetamine‐potentiated brain stimulation reward in rats Mark S. Todtenkopf, Krystal S. O’Neill, Kristina Kriksciukaite, Addiction Biology Placebo MicrospheresNeuromodulation TherapiesPsychopharmacologyIcss ParadigmOpioid Receptor Antagonism	2009	19
The Identification of the SIRT1 Activator SRT2104 as a Clinical Candidate Pui Yee Ng, Jean E. Bemis, Jeremy S. Disch, Letters in Drug Design & Discovery	2013	18
The safety and efficacy of PEN-221 somatostatin analog (SSA)-DM1 conjugate in patients (PTS) with advanced GI mid-gut neuroendocrine tumor (NET): Phase 2 results. Daniel M. Halperin, Melissa L. Johnson, Jennifer A. Chan, Journal of Clinical Oncology Cancer ManagementPathologyPreliminary EfficacyPre-clinical PharmacologyEndocrine Oncology	2021	15
Simple Method Provides Resolution of Albumin, Lipoprotein, Free Fraction, and Chylomicron To Enhance the Utility of Protein Binding Assays Adam Brockman, Haley Oller, Benoît Moreau, Journal of Medicinal Chemistry Proteinlipid InteractionMolecular BiologyAnalytical UltracentrifugationLipid MovementProtein Purification	2015	12
Novel Miniaturized Drug Conjugate Leverages HSP90-driven Tumor Accumulation to Overcome PI3K Inhibitor Delivery Challenges to Solid Tumors Samantha Perino, Benoît Moreau, Jessica Freda, Molecular Cancer Therapeutics	2020	11

Page 1